Abdominal Aortic Aneurysm

Abdominal aortic aneurysm (AAA) is a focal, permanent dilation of the abdominal aorta to a diameter of at least 3.0 cm, or to at least 1.5 times the expected normal diameter for the patient — most commonly below the renal arteries (infrarenal). It develops silently over years to decades as the aortic wall weakens, and the large majority of AAAs cause no symptoms at all until either an elective repair decision is reached or the aneurysm ruptures.

Management of AAA rests on 2 separate tracks that run in parallel and should never be confused with one another. The surveillance track applies to every small, stable aneurysm below the size threshold for repair: regular size-based ultrasound follow-up, plus standard, individualized cardiovascular risk-factor management and smoking cessation — but critically, no medication has been proven to shrink an aneurysm or reliably slow its growth. This is a genuine and common misconception, corrected explicitly and in detail in Choose Initial Treatment below.^[1][2] The repair track applies once the aneurysm reaches a size or growth-rate threshold, becomes symptomatic, or ruptures — a decision made by vascular surgery between endovascular (EVAR) and open surgical repair, not a pharmacotherapy escalation.^[1]

Most AAAs are found incidentally — on an ultrasound or CT ordered for an unrelated reason, on a screening ultrasound, or on physical examination as a pulsatile abdominal mass — rather than because the patient reports symptoms.

3D CT reconstruction of an infrarenal abdominal aortic aneurysm — the focal, permanent outward bulge of the aorta below the renal arteries. (Bakerstmd, modified from a reconstruction by Michel de Villeneuve; CC BY-SA 4.0, Wikimedia Commons)

Non-modifiable

• Age 65 years or older — risk increases steadily with age.
• Male sex — men are affected substantially more often than women, though women who do develop an AAA carry a higher rupture risk at any given diameter (see Choose Initial Treatment).
• A first-degree relative (parent, sibling, or child) with a history of AAA — a substantially and independently increased risk that applies regardless of the relative's own age or sex, and that is not captured by the general population screening criteria below (see Special Populations).
• A personal history of a thoracic or other peripheral arterial aneurysm.
• A genetic connective tissue disorder — Marfan syndrome, vascular Ehlers-Danlos syndrome, or Loeys-Dietz syndrome (see Special Populations).

Modifiable

• Smoking, active or past — the single strongest modifiable risk factor for both developing an AAA and for its growth and rupture once present; a history of ever having smoked substantially raises risk even after the patient has quit.
• Hypertension.
• Dyslipidemia.
• Established atherosclerotic disease elsewhere — coronary artery disease, peripheral artery disease, or cerebrovascular disease.
• Chronic obstructive pulmonary disease, independent of shared smoking history.

A genuine exception worth knowing

Diabetes mellitus is, unusually among vascular risk factors, consistently associated with a lower risk of developing an AAA and with slower growth of an AAA that is already present — the opposite direction of its effect on essentially every other atherosclerotic condition covered elsewhere in this library. This does not change how diabetes itself is managed, and a patient with diabetes and an established AAA still needs the same standard surveillance and risk-factor approach as any other patient — but it is a genuinely counterintuitive, useful teaching point when discussing risk with a patient or colleague.^[1]

History

• Age, sex, and smoking history (current or ever) — the core criteria for whether screening is indicated (see Choose Initial Treatment).
• Family history of AAA in a first-degree relative, personal history of another arterial aneurysm, and features suggesting a connective tissue disorder (tall stature, joint hypermobility, skin or vascular fragility) — each independently changes the screening and surveillance approach (see Special Populations).
• Cardiovascular risk factors and established atherosclerotic disease.
• Character, onset, and location of any abdominal, flank, or back pain, and any hemodynamic symptoms (lightheadedness, syncope) — critical for distinguishing stable surveillance from a possible rupture (see Red Flags & Refer).

Physical examination

Palpate for a pulsatile, expansile abdominal mass, usually above the umbilicus given the infrarenal location of most AAAs — but treat a normal examination as reassuring only, never as a way to rule out an AAA, since sensitivity is limited and falls further as body habitus increases. Assess hemodynamic stability directly (pulse, blood pressure, mental status, skin perfusion) in any patient with abdominal or back pain and a known or suspected AAA.

Ultrasound — the primary tool for both screening and surveillance

Sagittal abdominal ultrasound of an AAA, with the anteroposterior diameter (red dashed line) and maximal diameter (yellow dotted line) marked — the same real-time, radiation-free technique used for both one-time screening and ongoing surveillance. (Mikael Häggström, M.D.; CC0/public domain, Wikimedia Commons)

Abdominal ultrasound is inexpensive, involves no radiation or contrast exposure, and is the recommended modality for both initial screening and ongoing surveillance of a known AAA. Measure the maximum anteroposterior and transverse diameter in both transverse and sagittal planes, using a consistent measurement convention (outer wall to outer wall) between studies — switching modality or measurement technique between surveillance scans can create the appearance of growth or stability that is not real, so use the same modality, and ideally the same reporting convention, from one surveillance study to the next.^[1]

Surveillance intervals by diameter

^[1]

CT angiography

Reserve CT angiography for confirming a suspected rupture, for pre-operative anatomic planning once a patient is being evaluated for repair, and for post-repair surveillance (see Monitoring & Follow-Up) — not for routine ongoing surveillance of a stable, small AAA, where ultrasound is preferred to avoid cumulative radiation and contrast exposure over what can be years of follow-up. Where contrast is required in a patient with reduced renal function, apply the same contrast-associated AKI prevention framework used throughout this platform (see Acute Kidney Injury).

• Prevent rupture — the single overriding goal of AAA management, achieved primarily through correctly timed elective repair rather than through medical therapy.
• Detect an AAA in the population most likely to benefit from finding it — men aged 65-80 — through appropriate one-time screening.
• Track growth reliably with a consistent surveillance schedule and measurement technique, so the repair threshold is reached and acted on rather than missed.
• Reduce the patient's overall cardiovascular risk (myocardial infarction, stroke, cardiovascular death) using standard, individualized criteria — not because it changes the aneurysm itself, but because AAA is a marker of systemic atherosclerosis carrying its own independent cardiovascular risk.
• Achieve complete smoking cessation — the one intervention genuinely shown to slow AAA growth.
• Choose the repair approach (EVAR or open) appropriate to the patient's anatomy, surgical risk, and preferences once a repair threshold is reached.
• Sustain appropriate lifelong surveillance after repair to detect endoleak, device migration, or another late complication before it becomes an emergency.

Smoking cessation — the single most effective non-drug intervention

Complete smoking cessation is the one intervention with genuine evidence of slowing AAA growth and reducing rupture risk, distinct from the pharmacologic options addressed in Choose Initial Treatment and Drug Tables, none of which has shown this effect. Address it at every visit using the full assessment and pharmacotherapy framework in Tobacco Use Disorder — this is one of the highest-yield interventions available for a patient with an AAA and should never be deferred while other aspects of care are addressed.

General cardiovascular risk-reduction measures

Address diet, physical activity, weight, diabetes, hypertension, and dyslipidemia using the non-pharmacologic measures in their own chapters (Hypertension, Dyslipidemias, Diabetes Mellitus, Obesity) — these reduce the patient's overall cardiovascular risk but, unlike smoking cessation, have not been shown to change the aneurysm's growth or rupture risk directly.

Physical activity

Regular, moderate physical activity is not restricted by the presence of an AAA and has not been shown to increase rupture risk — reassure a patient who is avoiding normal daily activity or exercise out of unfounded fear that this is not necessary. Discuss any planned very strenuous or competitive activity individually with the patient's vascular surgeon, particularly for a larger or more borderline aneurysm, rather than applying a blanket restriction to every patient under surveillance.

Ensure the next surveillance appointment is actually booked

Before the visit ends, confirm the next surveillance ultrasound is scheduled and that the patient understands why — a documented gap where a small AAA is found but no follow-up interval is ever booked is a common, preventable system failure, and it is the surveillance schedule itself, not a medication, that is protecting the patient between now and the next visit.

Repair itself is the definitive non-pharmacologic treatment

Once an AAA reaches the repair threshold, EVAR or open surgical repair — not escalation of any medication — is the treatment that actually addresses the aneurysm; see Choose Initial Treatment and Drug Tables.

Pregnancy

An AAA in a patient of reproductive age is rare, since it typically develops after decades of arterial wall degeneration, but when it does occur it is disproportionately associated with an underlying genetic connective tissue disorder (Marfan syndrome, vascular Ehlers-Danlos syndrome, Loeys-Dietz syndrome) rather than the typical atherosclerotic AAA covered by the rest of this chapter. Manage an AAA discovered in pregnancy jointly with maternal-fetal medicine and vascular surgery from the outset. A ruptured AAA in pregnancy is managed with the same emergency protocol described in Choose Initial Treatment — immediate emergency response and repair — regardless of gestational age, since maternal survival is also the best chance of fetal survival. Statins are contraindicated in pregnancy — see Dyslipidemias. ACE inhibitors and ARBs are also contraindicated in pregnancy — see Hypertension.

Breastfeeding

None of the medications discussed in this chapter is prescribed for the AAA itself (see Drug Tables) — where a statin, antihypertensive, or antiplatelet agent is used for an independent indication in a breastfeeding patient, follow the standard breastfeeding-compatibility guidance in Dyslipidemias and Hypertension rather than any AAA-specific consideration.

Older adults and frailty

Most patients with an AAA are older adults, and this is exactly the population in whom the diameter-based repair threshold should be treated as a guide rather than an automatic trigger. Explicitly weigh surgical risk, life expectancy, frailty, and the patient's own preferences before proceeding to repair in a frail or very elderly patient near the threshold — continued surveillance without repair (sometimes called watchful waiting) is a reasonable, guideline-consistent choice for a patient in whom the risk of the repair procedure itself is judged to exceed the risk of the aneurysm over their expected remaining lifespan. Ensure this group still receives explicit rupture-symptom education (see Red Flags & Refer) even when repair has been deferred, since they remain at ongoing rupture risk.

Genetic connective tissue disorders

Marfan syndrome, vascular Ehlers-Danlos syndrome, and Loeys-Dietz syndrome cause aortic aneurysms — often thoracic as much as or more than abdominal — at smaller diameters and younger ages than typical atherosclerotic AAA, and behave more aggressively. Manage a patient with a known or suspected connective tissue disorder under specialist (genetics and vascular/cardiac surgery) direction using disorder-specific size thresholds and surveillance intervals, not the general population-based criteria in this chapter.

First-degree relatives

A first-degree relative of a patient with AAA carries a meaningfully increased risk independent of their own age, sex, or smoking history — consider one-time ultrasound screening at age 65-75, or beyond 75 if they are otherwise in good health, even if they would not otherwise meet the general population screening criteria in Choose Initial Treatment.^[1]

Renal impairment

Relevant mainly through CT angiography contrast exposure during pre-repair planning and post-EVAR surveillance (see Monitoring & Follow-Up) — apply the same contrast-associated AKI prevention framework used throughout this platform in a patient with reduced renal function (see Acute Kidney Injury), and favour ultrasound or a reduced-contrast protocol where it will still answer the clinical question.

During surveillance (before repair)

• Follow the size-based interval table in Assessment & Diagnosis, using a consistent imaging modality and measurement convention from one study to the next.
• Confirm the next surveillance appointment is actually booked before the patient leaves — an AAA found but never followed up is a preventable system failure, not a rare one.
• Reinforce smoking cessation and standard, individualized cardiovascular risk-factor management at every visit.
• Reassess against the repair threshold and rapid-growth criteria at every surveillance scan, not only when the patient happens to mention symptoms.
• Give every patient under surveillance explicit rupture-symptom education — what sudden severe abdominal or back pain with lightheadedness means, and to seek emergency care immediately rather than waiting to discuss it at the next scheduled visit.

After endovascular repair (EVAR)

EVAR requires lifelong surveillance imaging that open repair does not, since a stent-graft can develop an endoleak, migrate, or the aneurysm sac can continue to enlarge despite an apparently successful procedure — this ongoing imaging burden is one of the genuine trade-offs against EVAR's lower perioperative risk (see Choose Initial Treatment). Image with CT angiography or duplex ultrasound at 1 month, 6 months, and 12 months after the procedure, then annually indefinitely.^[1] Contrast-enhanced ultrasound is an emerging option at some centres to reduce a patient's cumulative radiation and contrast exposure over a lifetime of post-EVAR surveillance.

After open surgical repair

Open repair does not carry the same endoleak risk and generally does not require the same intensive, lifelong imaging surveillance once the patient has recovered — this durability is a genuine advantage of open repair over EVAR, weighed against its higher perioperative morbidity. Periodic follow-up remains appropriate at the treating surgeon's discretion to detect a late complication — anastomotic pseudoaneurysm, graft infection, or aortoenteric fistula — rather than being abandoned entirely.

Family screening

Use the diagnosis of a patient's own AAA as the trigger to discuss one-time screening in their first-degree relatives (see Special Populations) — this is easy to miss if the conversation focuses only on the index patient.

1. If a surveillance scan shows apparent rapid growth, confirm it with the same imaging modality and measurement convention used previously before acting — a change in modality or technique between studies can create the appearance of growth that is not real.
2. Confirm smoking cessation and standard cardiovascular risk-factor management are genuinely in place; but remember that continued slow, expected growth in a well-managed patient is not a sign that medical therapy has "failed", since no medication is expected to stop AAA growth in the first place — the surveillance schedule, not a drug, is what is protecting the patient.
3. Confirm whether the repair threshold or rapid-growth criteria have now been met, and refer for elective repair evaluation if so, rather than simply continuing the same surveillance interval.
4. If the patient declines repair, or is assessed as too high-risk for it, shift explicitly to a symptom-focused, shared decision-making conversation — reconfirm the patient understands the rupture symptoms to watch for and to seek emergency care immediately if they occur, since ongoing rupture risk remains even without planned repair.
5. If sac enlargement, an endoleak, or device migration is found on post-EVAR surveillance, refer to vascular surgery for reintervention — additional stent-graft components, embolization, or conversion to open repair, depending on the specific finding.
6. If a late complication of open repair is suspected — a new pulsatile mass at the incision (pseudoaneurysm), fever or wound changes suggesting graft infection, or gastrointestinal bleeding in a patient with a known aortic graft (raising concern for aortoenteric fistula) — refer urgently to vascular surgery; the last of these is a surgical emergency.

• Starting or intensifying a statin, ACE inhibitor/ARB, beta-blocker, or antibiotic specifically to try to shrink or slow an AAA — none of these has been shown to do this; the one genuinely effective non-surgical intervention is smoking cessation.
• Trusting a normal abdominal examination to exclude an AAA — physical examination has limited sensitivity, especially in a patient with obesity, and is never a substitute for ultrasound when there is genuine clinical concern.
• Missing a screening opportunity in an eligible man aged 65-80 because he has never smoked — the CTFPHC's screening recommendation for this age group is not limited to patients who have smoked.
• Screening a woman, or a man over 80, outside the specific circumstances (family history, connective tissue disorder, individualized shared decision-making) where it remains reasonable.
• Forgetting to ask about a first-degree relative's AAA history, which independently changes the screening recommendation regardless of the patient's own age, sex, or smoking status.
• Finding a small AAA on incidental imaging and not scheduling the next surveillance interval before the patient leaves.
• Switching imaging modality or measurement technique between surveillance scans without accounting for it, and misreading the apparent change as true growth or stability.
• Treating the size threshold for repair as an absolute trigger rather than a guide, without weighing surgical risk, life expectancy, and preferences in an older or frail patient.
• Assuming post-EVAR surveillance can be relaxed once a patient looks and feels well — endoleak and sac enlargement are often clinically silent and are caught only by the scheduled imaging itself.
• Delaying an emergency response for sudden severe abdominal or back pain with hypotension in an older patient while waiting for confirmatory imaging.
• Over-resuscitating a hemodynamically unstable, conscious patient with suspected rupture using aggressive IV fluids before bleeding is surgically controlled, instead of using permissive hypotension.

How to use this table: Doses are adult doses and require patient-specific confirmation (renal/hepatic function, weight, allergy history). Pediatric dosing is weight-based per the current product monograph unless stated. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.

Cardiovascular Risk-Reduction Therapy (individualized — see the evidence note below)

None of the medications in this table has been shown to slow AAA growth or reduce rupture risk on its own. Prescribe each one only when the patient's overall cardiovascular risk profile independently indicates it, using the standard criteria in Hypertension and Dyslipidemias — not because the AAA is present.

Antihypertensive Therapy

Treat hypertension itself to the standard target described in Hypertension — no antihypertensive class, including ACE inhibitors and ARBs, has been shown to slow AAA growth or reduce rupture risk beyond the blood pressure control any effective agent provides. Select and dose the specific agent using the Hypertension chapter's own framework rather than a AAA-specific one, since none exists.

Explicitly Not Recommended for Slowing AAA Growth or Reducing Rupture Risk

Do not start any of the following specifically because of the AAA. Continue an agent only if it is independently indicated for another condition.

Smoking Cessation Pharmacotherapy

The one intervention in this chapter with genuine evidence of slowing AAA growth is smoking cessation itself, not a drug directed at the aneurysm. See Tobacco Use Disorder for the complete first-line pharmacotherapy framework — varenicline, bupropion SR, and nicotine replacement therapy — and offer it to every patient who smokes at every visit.

Evidence note: the recommendation against using a statin, ACE inhibitor/ARB, beta-blocker, or antibiotic specifically to slow AAA growth is drawn from the current Society for Vascular Surgery AAA guideline, cross-checked against the largest randomized antibiotic trial.^[1][2]